Search hospitals > New Hampshire > Manchester
Solinsky Center for Cancer Care
Claim this profileManchester, New Hampshire 03103
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Prostate Cancer
146 reported clinical trials
2 medical researchers
Summary
Solinsky Center for Cancer Care is a medical facility located in Manchester, New Hampshire. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Solinsky Center for Cancer Care is involved with conducting 146 clinical trials across 141 conditions. There are 2 research doctors associated with this hospital, such as Douglas Weckstein, MD and Ali Fleury, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
Stage IV
HER2 positive
Top PIs
Douglas Weckstein, MDSolinsky Center for Cancer Care5 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
51 reported clinical trials
126 drugs studied
Ali Fleury, MDNH Oncology - Hematology, PA3 years of reported clinical research
Studies Multiple Myeloma
Studies Non-Hodgkin's Lymphoma
2 reported clinical trials
22 drugs studied
Clinical Trials running at Solinsky Center for Cancer Care
Breast Cancer
Prostate Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Anal Squamous Cell Carcinoma
Rectal Cancer
Bladder Cancer
Squamous Cell Carcinoma
Anal Cancer
Omitting Radiation Therapy
for Breast Cancer
This study is evaluating whether a type of radiation therapy may help prevent breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Solinsky Center for Cancer Care?
Solinsky Center for Cancer Care is a medical facility located in Manchester, New Hampshire. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Solinsky Center for Cancer Care is involved with conducting 146 clinical trials across 141 conditions. There are 2 research doctors associated with this hospital, such as Douglas Weckstein, MD and Ali Fleury, MD.